Healthcare
Sino Biological Launches 4RISE to Validate AI-Designed Protein Binders
Add Unite.AI to your preferred sources on Google
Key Points4RISE closes the gap between AI protein design and experimental proof by returning…
View more
- 4RISE closes the gap between AI protein design and experimental proof by returning binding data in days.
- Cell-free expression succeeded for more than 99% of candidates versus roughly 50–60% with HEK293.
- Tencent AI Lab used over 200 AI-designed enzymes across three validation rounds to refine its design framework.
Sino Biological launched 4RISE on November 13, 2026, a high-throughput wet-lab validation service for AI-designed protein binders. The company says the service can express proteins cell-free in as little as three hours and deliver sequence-to-AI-ready binding data in as little as three days, with real-time API access to structured results.
The service addresses the experimental step after computational design: AI-generated candidates must be produced and tested to confirm target-binding activity. Its documented workflow runs from sequence and testing-requirement submission through expression and purification, binding and kinetic analysis, optional developability and functional validation, and structured data delivery. The result is an experimental-feedback layer for subsequent research and design iterations.
Expression and Binding Measurements
XPressMAX, the company’s cell-free protein synthesis platform, supports miniproteins, VHHs, scFvs, Fabs, enzymes and cytokines. For formats requiring mammalian production, including full-length antibodies and Fc-fusion proteins, 4RISE offers HEK293 and CHO transient expression.
In a company-reported project involving more than 300 AI-designed minibinder variants, HEK293 expression succeeded for approximately 50–60% of candidates, compared with more than 99% using cell-free expression. The candidates then underwent multi-target bio-layer interferometry analysis.
Binding measurements use Carterra and Biacore surface plasmon resonance (SPR) and Octet bio-layer interferometry (BLI). The affinity and kinetic tier can report the affinity measure KD and the kinetic parameters kon and koff where supported by the assay design, adding quantitative measurements for lead selection.
Service Tiers and Assay Options
The published tiers separate initial hit discovery from purified, quantitative characterization:
| Service | Approach | Published price |
|---|---|---|
| Rapid Hit Discovery | Cell-free expression and single-point SPR/BLI screening of crude supernatants | From $67 per sequence |
| Comparative Binder Screening | Purified candidates at controlled concentrations, followed by single-point SPR/BLI | From $112 per sequence |
| Affinity & Kinetic Characterization | Purified candidates analyzed across multiple concentrations | From $142 per sequence |
| Specialized Binder Expression & Validation | Mammalian expression with single- or multi-concentration binding analysis | Custom quote |
Standalone cell-free expression starts at $47 per sequence.
Beyond binding, the service page lists more than 20 physicochemical assays, more than 1,000 protein bioactivity assays and more than 10 cell-based functional assays. Developability options examine thermal stability, aggregation, self-association, polyspecificity, hydrophobicity, expression and solubility. Functional options include neutralization, cell signaling, proliferation and enzyme-activity assays, extending evaluation from target binding to biological activity.
A project with Tencent AI Lab illustrates how those functional data can feed model development. The service page says Sino Biological supported more than 200 AI-designed enzymes across three rounds of design, validation and iteration, supplying gene synthesis, cell-free expression, purification and in vitro functional validation. The assays covered lysozyme activity, chitinase activity and high-temperature stability, providing experimental feedback for iterative optimization of Tencent’s Ontology Reinforcement Iteration protein-design framework.
Case Studies and Turnaround Times
In one company-reported validation project, direct SPR screening of cell-free supernatants evaluated more than 200 AI-designed binders without purification. It identified 11 binding-positive candidates and delivered gene-to-AI-ready data in three to four days.
A second company case study covered more than 2,000 de novo-designed scFv and VHH sequences. Gene synthesis, cell-free expression, purification and multi-target BLI analysis led to initial delivery of purified antibodies and binding data in seven to eight days.
Those examples put the three-day claim in context: the fastest turnaround applies to a particular sequence-to-binding-data workflow, while the larger purified-antibody project had a longer initial-delivery window. For AI drug-discovery teams, the practical value is a standardized route from large sequence libraries to experimentally ranked candidates, with purified-protein, developability and functional evidence available for subsequent research decisions.
